Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M13,466Revenue $M355Net Margin (%)-11.2Z-Score7.5
Enterprise Value $M13,615EPS $-0.6Operating Margin %1.0F-Score3
P/E(ttm))0Cash Flow Per Share $-1.3Pre-tax Margin (%)-11.2Higher ROA y-yN
Price/Book010-y EBITDA Growth Rate %0Quick Ratio5.3Cash flow > EarningsY
Price/Sales28.75-y EBITDA Growth Rate %0Current Ratio5.3Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %-70.3ROA % (ttm)-8.7Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M169ROI % (ttm)-131.6Gross Margin Increase y-yN

Gurus Latest Trades with INCY

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
INCYKen Fisher 2014-12-31 Add$45.6 - $78.89
($65.29)
$ 79.7122%Add 97.08%14,870
INCYKen Fisher 2014-09-30 Reduce$45.35 - $55.78
($50.07)
$ 79.7159%Reduce -38.28%7,545
INCYVanguard Health Care Fund 2014-06-30 Add0.68%$43.1 - $56.39
($50.98)
$ 79.7156%Add 95.66%9,591,143
INCYKen Fisher 2014-06-30 Buy $43.1 - $56.39
($50.98)
$ 79.7156%New holding, 12225 sh.12,225
INCYMariko Gordon 2014-06-30 Reduce-0.19%$43.1 - $56.39
($50.98)
$ 79.7156%Reduce -78.93%23,728
INCYGeorge Soros 2014-06-30 Sold Out -0.01%$43.1 - $56.39
($50.98)
$ 79.7156%Sold Out0
INCYGeorge Soros 2014-03-31 Buy 0.01%$49.94 - $68.83
($61.83)
$ 79.7129%New holding, 23200 sh.23,200
INCYMariko Gordon 2013-12-31 Reduce-0.06%$34.71 - $51.34
($43.45)
$ 79.7184%Reduce -20.5%128,959
INCYVanguard Health Care Fund 2013-06-30 Add0.05%$19.07 - $24.49
($21.85)
$ 79.71265%Add 21.52%3,807,443
INCYVanguard Health Care Fund 2013-03-31 Buy 0.29%$16.61 - $24.95
($20.44)
$ 79.71290%New holding, 3133100 sh.3,133,100
INCYGeorge Soros 2011-03-31 Sold Out $13.37 - $16.56
($14.71)
$ 79.71442%Sold Out0
INCYGeorge Soros 2010-12-31 Buy $14.51 - $17.17
($16.13)
$ 79.71394%New holding, 15000 sh.15,000
INCYBill Gates 2009-06-30 Sold Out -0.01%$2.06 - $3.84
($2.79)
$ 79.712757%Sold Out0
INCYJean-Marie Eveillard 2009-03-31 Sold Out $2.14 - $3.78
($2.9)
$ 79.712649%Sold Out0
INCYJean-Marie Eveillard 2008-12-31 Buy $2.82 - $4.89
($3.8)
$ 79.711998%New holding, 11300 sh.11,300
INCYGeorge Soros 2008-09-30 Sold Out -0.02%$7.31 - $10.23
($9.2)
$ 79.71766%Sold Out0
INCYGeorge Soros 2008-06-30 Add0.01%$7.6 - $11.27
($9.8)
$ 79.71713%Add 52.29%74,558
INCYGeorge Soros 2008-03-31 Reduce-0.01%$9.27 - $12.36
($10.6)
$ 79.71652%Reduce -57.34%48,958
INCYGeorge Soros 2007-12-31 Reduce-0.03%$7.85 - $10.59
($8.9)
$ 79.71796%Reduce -45.42%114,758
INCYJean-Marie Eveillard 2007-09-30 Sold Out $4.81 - $7.15
($5.9)
$ 79.711251%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

INCY is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
INCY Ken Fisher 2014-12-3114,8700.010+97.08%
INCY Mariko Gordon 2014-09-3025,2830.010.05+6.55%
INCY Vanguard Health Care Fund 2014-09-3010,174,3436.021.3+6.08%
INCY - CALLMariko Gordon 2014-09-3016,5000.010.04
INCY Ken Fisher 2014-09-307,54500-38.28%
Premium Most recent portfolio changes are included for Premium Members only!


INCY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Siegel Eric H.EVP, General Counsel 2015-01-26Sell13,542$79.851.87view
Daly James MEVP, Chief Commercial Officer 2015-01-23Sell11,109$77.684.71view
SWAIN PAULA JEVP, Human Resources 2015-01-20Sell17,500$74.179.67view
Levy Richard SEVP, Chief Drug Dev&Medical Of 2015-01-16Sell12,000$73.0711.32view
Siegel Eric H.EVP, General Counsel 2015-01-08Sell15,626$758.45view
Levy Richard SEVP, Chief Drug Dev&Medical Of 2015-01-06Sell25,000$71.8413.22view
SWAIN PAULA JEVP, Human Resources 2015-01-05Sell17,500$73.910.07view
Daly James MEVP, Chief Commercial Officer 2014-12-23Sell11,113$74.439.28view
Levy Richard SEVP, Chief Drug Dev&Medical Of 2014-12-16Sell12,000$72.3612.41view
DE SCHUTTER RICHARD UChairman 2014-12-02Sell50,000$74.898.61view

Press Releases about INCY :

Quarterly/Annual Reports about INCY:

News about INCY:

Articles On GuruFocus.com
Weekly CFO Sells Highlight: Aramark, Incyte Corp Ltd., Facebook Inc. Jun 09 2014 
Weekly Insider Sells Highlight: ARMK, INCY, ESC, HUN Jun 08 2014 
Weekly Insider Sells Highlight: CPN, INCY, GPK, CODE Feb 23 2014 
Weekly CFO Sells Highlight: Pandora Media Inc, Incyte Corp Ltd, Google Inc, American Airlines Group Feb 24 2014 
Weekly CEO Sells Highlight: ExOne Co, Atmel Corporation, Best Buy and Incyte Corp Ltd. Sep 22 2013 
Weekly CFO Sells Highlight: INTU, INCY, RLD, MIDD, XONE Sep 15 2013 
Weekly CEO Sells Highlight: DIS, LMT, INCY, ADBE May 14 2012 
Weekly Top Insider Buys: VTR, INCY, FULT, HMA, CMC Jan 23 2012 
04 stocks with insider buying of more than $1.5 million since beginning of 2012 Jan 22 2012 
Weekly CFO Sales Highlight: EPIQ, INCY, AVB, JOSB, PCS, FLO Jun 12 2011 

More From Our Partners
Incyte's Phase III RESPONSE Data on Jakafi Published - Analyst Blog Jan 29 2015 - ZACKS

More From Other Websites
Incyte's Phase III RESPONSE Data on Jakafi Published - Analyst Blog Jan 29 2015
Incyte Announces Publication of Phase III RESPONSE Trial in Patients with Polycythemia Vera in New... Jan 28 2015
5:00 pm Incyte announces publication of Phase III RESPONSE trial in patients with Polycythemia Vera... Jan 28 2015
Will Incyte (INCY) Continue to Surge Higher? - Tale of the Tape Jan 28 2015
Incyte to Report Fourth Quarter/Year-End 2014 Financial Results on February 12 Jan 27 2015
INCYTE CORP Files SEC form 8-K, Change in Directors or Principal Officers Jan 26 2015
Incyte Earns $25 Million Milestone as Jakavi® (ruxolitinib) Recommended for Approval in Europe for... Jan 23 2015
The Zacks Analyst Blog Highlights: NPS Pharmaceuticals, Celgene, Pharmacyclics, Agenus and Incyte -... Jan 15 2015
AstraZeneca Inks Immuno-Oncology Agreement with Omnis - Analyst Blog Jan 14 2015
Biotech Stock Roundup: Shire to Acquire NPSP, Celgene & Pharmacyclics Give Strong Outlook - Analyst... Jan 14 2015
Health care's strong 2015 outlook Jan 13 2015
Calls look for quick rally in Incyte Jan 12 2015
INCYTE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and... Jan 12 2015
INCYTE CORP Files SEC form 8-K, Change in Directors or Principal Officers Jan 09 2015
A volatile end to a very volatile week... Jan 09 2015
Has Agenus Run Too Much? Jan 09 2015
Incyte Board Appoints Two New Directors Jan 09 2015
Incyte Board Appoints Two New Directors Jan 09 2015
Incyte and Agenus Announce Global Alliance to Develop Novel Immuno-Oncology Antibodies Jan 09 2015
Incyte and Agenus Announce Global Alliance to Develop Novel Immuno-Oncology Antibodies Jan 09 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK